Difference between revisions of "HIV-associated lymphoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 55: Line 55:
 
# Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, Neely J, Arndt C, Nieder M, Jaffe E, Wittes RA, Horak ID. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996 Mar;14(3):925-34. [http://jco.ascopubs.org/content/14/3/925.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8622041 PubMed]
 
# Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, Neely J, Arndt C, Nieder M, Jaffe E, Wittes RA, Horak ID. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996 Mar;14(3):925-34. [http://jco.ascopubs.org/content/14/3/925.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/8622041 PubMed]
 
# Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, Goy A, Hedrick E, Zelenetz AD, Noy A. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003 Sep 15;98(6):1196-205. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.11628/abstract link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/12973843 PubMed]
 
# Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, Goy A, Hedrick E, Zelenetz AD, Noy A. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003 Sep 15;98(6):1196-205. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.11628/abstract link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/12973843 PubMed]
 +
 +
=DR-COP=
 +
DR-COP: '''<u>D</u>'''oxil (pegylated liposomal doxorubicin), '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone
 +
 +
[[Levels of Evidence]]: 
 +
<span
 +
style="background:#EEEE00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase II</span>
 +
 +
==Regimen==
 +
*[[Doxorubicin liposomal (Doxil)]] 40 mg/m2 IV on day 1
 +
*[[Rituximab (Rituxan)]] 375 mg/m2 IV on day 1
 +
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m2 IV on day 1
 +
*[[Vincristine (Oncovin)]] 1.4 mg/m2/day (capped at 2mg) IV on day 1
 +
*[[Prednisone (Sterapred)]] 100 mg PO daily on days 1-5
 +
*Antiretroviral therapy is given concomitantly
 +
 +
'''21 to 28 day cycles up to 6 cycles'''
 +
 +
Supportive medications:
 +
*[[Filgrastim (Neupogen)]] OR [[Pegfilgrastim (Neulasta)]] OR [[Sargramostim (Leukine)]] starting on day 3 until beyond nadir
 +
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] or other PCP/PJP prophylaxis
 +
*Oral quinaolone if CD4 cell count < 100 at entry or during treatment
 +
 +
==References==
 +
# Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A. Pegylated Liposomal Doxorubicin, Rituximab, Cyclophosphamide, Vincristine, and Prednisone in AIDS-Related Lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol. 2012 Nov 19. [Epub ahead of print] [http://jco.ascopubs.org/content/31/1/58.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23169503 PubMed]
  
 
=R-CODOX-M/IVAC=
 
=R-CODOX-M/IVAC=

Revision as of 19:19, 31 December 2012

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.


CODOX-M/IVAC

CODOX-M: Cyclophosphamide, Oncovin, DOXorubicin, M ethotrexate

IVAC: Ifosfamide, Vepesid (etoposide), AC Ara-C (cytarabine)

Part 1: CODOX-M

Age 65 years or younger:

Age more than 65 years:

  • Folinic acid (Leucovorin) 15 mg/m2 IV Q3H, starting 36 hours after start of IV methotrexate until 48 hours, then Q6H until methotrexate level undetectable

Supportive medications:

Part 2: IVAC

Age 65 years or younger:

Age more than 65 years:

Supportive medications:

References

  1. Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, Neely J, Arndt C, Nieder M, Jaffe E, Wittes RA, Horak ID. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996 Mar;14(3):925-34. link to original article contains verified protocol PubMed
  2. Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, Goy A, Hedrick E, Zelenetz AD, Noy A. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003 Sep 15;98(6):1196-205. link to original article PubMed

DR-COP

DR-COP: Doxil (pegylated liposomal doxorubicin), Rituximab, Cyclophosphamide, Oncovin, Prednisone

Levels of Evidence: Phase II

Regimen

21 to 28 day cycles up to 6 cycles

Supportive medications:

References

  1. Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A. Pegylated Liposomal Doxorubicin, Rituximab, Cyclophosphamide, Vincristine, and Prednisone in AIDS-Related Lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol. 2012 Nov 19. [Epub ahead of print] link to original article contains verified protocol PubMed

R-CODOX-M/IVAC

Regimen

To be completed

References

  1. Kassam S, Bower M, Lee SM, de Vos J, Fields P, Gandhi S, Nelson M, Montoto S, Tenant-Flowers M, Burns F, Marcus R, Edwards SG, Cwynarski K. A retrospective, multi-center analysis of treatment intensification for HIV-positive patients with high-risk diffuse large B-cell lymphoma. Leuk Lymphoma. 2012 Dec 3. [Epub ahead of print] link to original article PubMed

R-EPOCH, dose-escalated (EPOCH-R)

Regimen

21-day cycles x 6-8 cycles

Supportive medications:

  • EITHER Filgrastim (Neupogen) 5 mcg/kg SC daily, starting 24 hours after EPOCH is completed and continuing until "neutrophil recovery"—no absolute count specified
  • OR Pegfilgrastim (Neulasta) 6 mg SC x1 24 hours after EPOCH is completed
  • Trimethoprim/Sulfamethoxazole (Bactrim DS) 160/800 mg PO 3x per week (e.g. Monday, Wednesday, Friday)
  • Fluconazole (Diflucan) 100 mg PO daily
  • Ciprofloxacin (Cipro) 500 mg PO BID, starting on day 8 and to continue to at least day 15 or postnadir ANC of at least 1000
    • Other fluoroquinolone can be used at discretion of physician

References

  1. Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R; AIDS Malignancy Consortium. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010 Apr 15;115(15):3008-16. Epub 2009 Dec 18. link to original article contains verified protocol PubMed